For sales & orders : / For techical support :
: +86-23-67567091
Home > News >

Anti-SARS-CoV-2 Neutralizing Antibody (NtAb) ELISA

2020-09-27 15:56:41

Dear Customers,

       We are glad to let you know that we released a new product: the Anti-SARS-CoV-2 Neutralizing Antibody (NtAb) ELISA. This kit is based on the competitive ELISA, it is a blocking ELISA detection tool, which mimics the virus neutralization process. It is for qualitative detection of any antibodies that neutralize the interaction of SARS-CoV-2 Spike RBD-ACE2 in serum, plasma.

       Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, or 2019-nCoV) is an enveloped non-segmented positive-sense RNA virus. It is the cause of coronavirus disease 2019 (COVID-19), which is contagious in humans. SARS-CoV-2 has several structural proteins including spike (S), envelope (E),membrane (M) and nucleocapsid (N). The spike protein (S) contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor, angiotensin converting enzyme-2 (ACE2). It is found that the RBD of the SARS-CoV-2 S protein strongly interacts with the human ACE2 receptor leading to endocytosis into the host cells of the deep lung and viral replication. Infection with the SARS-CoV-2 initiates an immune response, which includes the production of antibodies in the blood. The secreted antibodies provide protection against future infections from viruses, because they remain in the circulatory system for months to years after infection and will bind quickly and strongly to the pathogen to block cellular infiltration and replication. These antibodies are named neutralizing antibodies. 

       This kit can detect circulating neutralizing antibodies against SARS-CoV-2 that block the interaction between the receptor binding domain of the viral spike glycoprotein (RBD) with the ACE2 cell surface receptor. The detection is not limited by both species and antibody isotypes.

       Please check our product page or search its catalog # BEK1265 in our website for details, thanks.